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The emergence of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp.
has necessitated the search for alternative parenteral agents such as the polymyxins. The National Committee
for Clinical Laboratory Standards (NCCLS) documents do not currently provide interpretative criteria for the
testing of the polymyxins, colistin and polymyxin B. Therefore, an evaluation of the antimicrobial activity of
colistin and polymyxin B was initiated using 200 bloodstream infection pathogens collected through the
SENTRY Antimicrobial Surveillance Program. All susceptibility tests were performed according to the NCCLS
recommendations. Polymyxin B and colistin displayed a nearly identical spectrum of activity, exhibiting
excellent potency against P. aeruginosa (MIC90, 2 mg/ml) and Acinetobacter sp. (MIC90, 2 mg/ml). In contrast,
they showed limited activity against some other nonfermentative bacilli such as Burkholderia cepacia (MIC90,
>128 mg/ml). Excellent correlation was achieved between broth microdilution and agar dilution tests (r 5 0.96
to 0.98); 94.3% of the results were 61 log2 dilution between the methods used for both compounds. At a
resistance breakpoint of >4 mg/ml for both agents, unacceptable false-susceptible or very major errors were
noted for colistin (5%) and polymyxin B (6%). Modified zone criteria for colistin (<11 and >14 mm) and
polymyxin B (<10 and >14 mm) were suggested, but some degree of error persisted (>3.5%). It is recom-
mended that all susceptible disk diffusion results be confirmed by MIC tests using the preferred reference
NCCLS method. The quality control (QC) ranges listed in the product package insert require an adjusted
range by approximately 3 mm for both NCCLS gram-negative quality control strains. This evaluation of in
vitro susceptibility test methods for the polymyxin class drugs confirmed continued serious testing error with
the disk diffusion method, the possible need for breakpoint adjustments, and the recalculation of disk diffusion
QC ranges. Clinical laboratories should exclusively use MIC methods to assist the therapeutic application of
colistin or polymyxin B until disk diffusion test modifications are sanctioned and published by the NCCLS.
Polymyxins are a group of polycationic peptides naturally
synthesized by Bacillus polymyxa, a nonactinomycete bacterium
(7). Members of this class (colistin and polymyxin B) act pri-
marily on the gram-negative bacterial cell wall, leading to rapid
permeability changes in the cytoplasmic membrane and ulti-
mately to cell death. These drugs cross the bacterial outer
membrane (self-promoted pathway) by competitive divalent
cation displacement by the bulky polycations, which nonco-
valently cross the bridge adjacent to the polysaccharide com-
ponent. Consequently, the bacterial outer membrane becomes
distorted and more permeable, permitting increased uptake of
the permeabilizing compounds (10, 19). Of the five recognized
polymyxins (A to E), only polymyxins B and E (colistin) have
advanced to therapeutic use.
Polymyxin B and colistin have been demonstrated to be
active against Pseudomonas aeruginosa. Four decades ago,
polymyxins were among the few treatments available for seri-
ous P. aeruginosa infections. Since 1980 other, less-toxic anti-
microbial agents have become available, and the clinical use of
polymyxins has been limited to topical formulations for the
treatment of skin, ear, and ocular diseases. Polymyxin B topical
formulations also have been used prophylatically for the pre-
vention of infection in neutropenic or cystic fibrosis patients (6,
11). Recently, the emergence of multidrug-resistant P. aerugi-
nosa and Acinetobacter spp. isolates causing life-threatening
infections has restored the potential therapeutic indication for
the parenteral use of polymyxins (1, 12, 20), usually colistin in
North American medical centers. Consequently, clinical micro-
biology laboratories should be able to perform reliable suscep-
tibility testing for drugs in this class.
The National Committee on Clinical Laboratory Standards
(NCCLS) does not provide guidance for the testing of poly-
myxins. In fact, the resistance breakpoint criteria for polymy-
xins were last available in the 1981 NCCLS Approved Standard
M2-A2 S2 (15); however, with the very restricted use of poly-
myxins, the published information was later withdrawn.
In this study, the antimicrobial activities of the polymyxins
were evaluated against selected contemporary bacterial patho-
gens. The correlation of the broth microdilution, disk diffusion,
and agar dilution methods was performed to determine the
susceptibility criteria for polymyxins. Disk diffusion quality
controls for Escherichia coli ATCC 25922 and P. aeruginosa
ATCC 27853 were also carried out to validate method control
and the interpretation criteria only found in the disk product
package insert.
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Bacterial strains. Bloodstream isolates collected from distinct geographic ar-
eas during 1998 through the SENTRY Antimicrobial Surveillance Program were
evaluated in this study. Only one isolate per patient was included. The distribu-
tion of species was as follows: Acinetobacter spp. (60), Burkholderia cepacia (12),
Enterobacter spp. (5), Klebsiella pneumoniae (9), Morganella morganii (2), Proteus
mirabilis (2), Providencia rettgeri (2), Pseudomonas aeruginosa (80), Serratia mar-
cescens (5), and Stenotrophomonas maltophilia (23). The bacterial identifications
were confirmed by routine laboratory methods in laboratories at the University
of Iowa College of Medicine (Iowa City, Iowa). The isolates were selected at
random, but nearly 20% of the P. aeruginosa and Acinetobacter spp. isolates were
chosen to be resistant to carbapenems (imipenem, meropenem), and all K.
pneumoniae were extended-spectrum b-lactamases (ESBL)-producing strains.
Antimicrobial agents. Polymyxin B and colistin sulfate powders were obtained
from Sigma Chemical (St. Louis, Mo.). Other tested drugs were obtained com-
mercially or provided by their respective manufacturers.
Susceptibility testing. Antimicrobial susceptibility testing was performed as
recommended by the NCCLS (16, 17). All bacterial isolates were tested by broth
microdilution and disk diffusion tests, while only 35 isolates representing all the
species were tested by agar dilution to provide a comparison to its broth mi-
crodilution test results. These organisms were selected to provide a wide range
of polymyxin MICs (Fig. 1). The susceptibility test medium was Mueller-Hinton
agar or broth according to the test performed. Microdilution broth trays were
prepared by PML Microbiologics (Wilsonville, Oreg.) and stored at 270°C until
used. E. coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as quality
control (QC) strains.
QC study. Determination of the disk diffusion QC results for E. coli ATCC
25922 and P. aeruginosa ATCC 27853 was done by testing two or three 300-U
polymyxin B disks from two different lots (BD Microbiology Systems, Cock-
eysville, Md.; Difco Laboratories, Detroit, Mich.). Three 10-mg colistin disks
were tested from a single lot (BD Microbiology Systems). The tests were repli-
cated 10 times and read by four different observers. This study produced at least
20 replicate zone diameters for each disk and 200 and 120 zones overall for
polymyxin B and colistin, respectively.
Statistical methods. The MIC results of the broth microdilution and agar
dilution methods were compared by regression analysis. Essential agreement was
defined to be when the broth microdilution results agreed within 61-log2 dilution
of the reference agar dilution test. A result was determined to be discrepant if
there was a $2-log2 dilution difference between test results. Broth microdilution
results were also compared to the zones of inhibition produced by the polymyxin
disk diffusion tests also using the method of least squares as applied to comput-
ers.
Categorical agreement was defined if the test results were within the same
susceptibility category, and errors were determined by methods published in
NCCLS M23-A2 (18) and ranked as follows: very major error, false-susceptible
result by the disk diffusion test; major error, false-resistant result produced by the
disk diffusion test; and minor error, intermediate result by the disk diffusion
method and a resistant or susceptible category for the dilution test (only two
categories have been suggested).
RESULTS
Polymyxin antimicrobial activity. Tables 1 and 2 (colistin
only) summarize the activities of the polymyxins against 200
contemporary gram-negative clinical isolates. Polymyxin B and
FIG. 1. Scattergram results for colistin comparing broth microdilution MICs with the reference agar dilution method against 35 recent clinical
isolates selected to possess a wide range of MIC values. The diagonal line represents complete agreement, and the numbers represent the
occurrences observed at each point. The broken lines represent 61-log2 MIC agreement limits between test results. Horizontal and vertical broken
lines indicate the resistant MIC breakpoints ($4 mg/ml).
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TABLE 1. Antimicrobial activity of colistin and polymyxin B compared to other antimicrobial agents against 200 contemporary
bacterial isolates




Acinetobacter spp. (60) Polymyxin B #1 2 #1–8 95.0a
Colistin #1 2 #1–32 96.7a
Ceftazidime 8 .32 #0.25–.32 55.0
Cefepime 8 .32 #0.25–.32 55.0
Imipenem 0.5 .16 #0.12–.16 80.0
Meropenem 1 .16 #0.12–.16 80.0
Ciprofloxacin 0.5 .4 #0.03–.4 58.3
Levofloxacin 0.25 .8 #0.06–.8 60.0
Amikacin 16 .64 #1–.64 51.7
Tobramycin 8 .16 0.5–.16 48.3
Doxycycline 0.25 4 #0.12–.16 91.7
TMP-SMX 2 .4 #0.06–.4 50.0
B. cepacia (12) Polymyxin B .128 .128 .128 0.0a
Colistin .128 .128 .128 0.0a
Ceftazidime 4 32 2–.32 66.7
Cefepime 32 .32 4–.32 8.3
Imipenem 8 .16 0.25–.16 16.7
Meropenem 2 16 0.25–16 75.0
Ciprofloxacin 1 2 0.5–4 58.3
Levofloxacin 2 8 1–8 75.0
Amikacin .64 .64 32–.64 0.0
Tobramycin .16 .16 2–.16 8.3
Doxycycline 4 .16 1–.16 50.0
TMP-SMX 1 2 0.5–2 100.0
K. pneumoniae (9) Polymyxin B #1 #1–2 100.0a
Colistin #1 #1–2 100.0a
Ceftazidime 4 1–16 77.8
Cefepime 2 #0.25–.32 66.7
Imipenem 0.25 #0.12–0.5 100.0
Meropenem #0.12 #0.12–0.25 100.0
Ciprofloxacin #0.03 #0.03–0.25 100.0
Levofloxacin #0.06 #0.06–0.25 100.0
Amikacin 8 #1–64 88.9
Tobramycin .16 #0.25–.16 44.4
Doxycycline 1 0.5–.16 88.9
TMP-SMX 1 0.25–.4 77.8
P. aeruginosa (80) Polymyxin B #1 2 #1–2 100.0a
Colistin #1 #1 #1–2 100.0a
Ceftazidime 2 .32 #0.25–.32 68.8
Cefepime 2 16 #0.25–.32 80.0
Imipenem 2 .16 #0.12–.16 78.8
Meropenem 0.5 8 #0.12–.16 85.0
Ciprofloxacin 0.12 4 #0.03–.4 81.3
Levofloxacin 0.5 .8 #0.06–.8 78.8
Amikacin 2 8 #1–.64 93.8
Tobramycin 0.5 2 #0.25–.16 91.3
Doxycycline 16 .16 0.5–.16 7.5
TMP-SMX .4 .4 0.12–.4 5.0
S. maltophilia (23) Polymyxin B 2 8 #1–64 73.9a
Colistin #1 32 #1–64 73.9a
Ceftazidime 8 32 1–.32 65.2
Cefepime 16 32 1–.32 26.1
Imipenem .16 .16 .16 0.0
Meropenem .16 .16 8–.16 0.0
Ciprofloxacin 1 .4 0.25–.4 52.2
Levofloxacin 0.5 4 0.12–.8 87.0
Amikacin .64 .64 8–.64 4.3
Tobramycin .16 .16 2–.16 8.7
Doxycycline 1 2 #0.12–8 95.7
TMP-SMX 0.5 .4 0.12–.4 73.9
Continued on following page
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colistin displayed nearly identical spectrums of activity, exhib-
iting usable potency against P. aeruginosa (MIC90, 2 mg/ml)
and Acinetobacter sp. (MIC90, 2 mg/ml). In contrast, they
showed no activity against some other nonfermentative bacilli
such as B. cepacia (MIC90, $128 mg/ml). Nearly three-quarters
of the S. maltophilia isolates were inhibited at 4 mg/ml of both
compounds. The polymyxins (MIC50, #1 mg/ml) were eight-
fold more potent than ceftazidime (MIC50, 8 mg/ml) and
cefepime (MIC50, 8 mg/ml) and showed similar activity to that
displayed by the carbapenems against Acinetobacter sp. strains.
Only three carbapenem-resistant Acinetobacter sp. isolates
were not inhibited at polymyxin MICs of #2 mg/ml. Although
levofloxacin and doxycycline exhibited similar potency against
Acinetobacter sp., only doxycycline showed a susceptibility rate
greater than 90.0%.
Against P. aeruginosa, colistin and polymyxin B were at least
twofold more potent than ceftazidime, cefepime, and amikacin
(MICs, 2 mg/ml). In contrast, polymyxin B and colistin were not
active against B. cepacia (MICs, $128 mg/ml). Against this
pathogen, the most active compounds based on potency and
susceptibility rate were: trimethoprim-sulfamethoxazole (MIC50,
1 mg/ml), 100.0% susceptible) . meropenem 5 levofloxacin
(MIC50, 1 mg/ml, 75.0%). Ceftazidime and meropenem were
fourfold more potent than comparative drugs in their classes,
cefepime and imipenem, respectively. The aminoglycosides
showed very poor activity against these isolates.
Among the selected S. maltophilia isolates, 26.2% isolates
were resistant to polymyxins. Doxycycline showed the highest
susceptibility rate (95.7%) for S. maltophilia, followed by levo-
floxacin (87.0%), and the usual “drug of choice” trimethoprim-
sulfamethoxazole (73.9%). Carbapenems and aminoglycosides
were not active against this pathogen.
Polymyxin B and colistin also demonstrated excellent activity
against the ESBL-producing K. pneumoniae isolates (MIC50,
#1 mg/ml). Although many ESBL-producing isolates show re-
sistance to fluoroquinolones, the isolates tested in this study
were very susceptible to this class of agents. Carbapenems were
also potent, exhibiting 100.0% susceptibility rates.
Against AmpC-cephalosporinase producers, the activities of
polymyxin B and colistin varied from excellent (Enterobacter
aerogenes and M. morganii MICs, #1 mg/ml) to poor (S. mar-
cescens and P. rettgeri MICs, $128 mg/ml). Carbapenems and
cefepime were the only agents with complete activity and spec-
trum versus these Enterobacteriaceae (except one S. marcescens
isolate with a cefepime MIC of $32 mg/ml).
TABLE 1—Continued




Othersc (16) Polymyxin B 64 .128 #1–.128 37.5a
Colistin 64 .128 #1–.128 37.5a
Ceftazidime #0.25 32 #0.25–.32 62.5
Cefepime #0.25 2 #0.25–.32 93.8
Imipenem 0.5 4 0.25–4 100.0
Meropenem #0.12 #0.12 #0.12 100.0
Ciprofloxacin #0.03 4 #0.03–.4 81.3
Levofloxacin #0.06 4 #0.06–.8 81.3
Amikacin 4 8 #1–8 100.0
Tobramycin 1 8 0.5–.16 87.5
Doxycycline 2 .16 0.25–.16 62.5
TMP-SMX 0.5 .4 0.12–.4 68.8
a Resistant strains with colistin and polymyxin B MICs of $4 mg/ml.
b TMP-SMX, trimethoprim-sulfamethoxazole.
c E. aerogenes (four strains), E. cloacae (one strain), M. morganii (two strains), P. mirabilis (two strains), P. rettgeri (two strains), and S. marcescens (five strains).
TABLE 2. Colistin MIC frequency distribution tested against a diverse sample of bacterial species
Organism (no. of isolates tested)
No. of isolates (%) inhibited at MIC (mg/ml) of:
#1 2 4 8 16 32 64 $128
Acinetobacter spp. (60) 54 (90.0) 3 (95.0) 1 (96.7) 1 (98.3) 1 (100.0)
B. cepacia (12) 12 (100.0)
Enterobacter spp. (5) 4 (80.0)a 1 (100.0)b
Indole-positive group (4) 2 (50.0)c 2 (100.0)d
K. pneumoniae (9) 8 (88.9) 1 (100.0)
Proteus mirabilis (2) 1 (50.0) 1 (100.0)
P. aeruginosa (80) 79 (98.8) 1 (100.0)
S. marcescens (5) 5 (100.0)
S. maltophilia (23) 13 (56.5) 3 (69.6) 1 (73.9) 1 (78.3) 2 (87.0) 2 (95.7) 1 (100.0)
All strains (200) 160 (80.0) 8 (84.0) 2 (85.0) 2 (86.0) 2 (87.0) 4 (89.0) 2 (90.0) 20 (100.0)
a E. aerogenes (four strains)
b E. cloacae (one strain).
c M. morganii (two strains)
d P. rettgeri (two strains).
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Comparisons of broth microdilution and agar dilution
methods. Figure 1 shows the comparative analysis between the
reference dilution tests for colistin using a subset of 35 strains
having a wide range of polymyxins MICs. Polymyxin B (data
not shown) and colistin broth microdilution MICs showed ex-
cellent correlation with agar dilution test results, exhibiting an
essential agreement of 94.3% (61-log2 dilution) for both com-
pounds (r 5 0.96 to 0.98). Only two organisms showed agar
dilution MIC values at fourfold higher than broth microdilu-
tion MICs for each compound. A trend toward higher MIC
results with the agar method was observed. The discrepant results
between the reference MIC tests would result in a single change
in the susceptibility category (one dilution variation; Fig. 1), if the
resistance breakpoint of $4 mg/ml was applied.
Comparison of disk diffusion zones to reference broth mi-
crodilution MICs. Figures 2 and 3 present the scattergram for
200 bacterial strains tested by broth microdilution and stan-
dardized disk diffusion methods against colistin and polymyxin
B, respectively. For both polymyxins, two distinct large bacte-
rial populations exhibiting MICs of #2 and $128 mg/ml were
detected. When the previously suggested interpretative resis-
tance criteria for colistin (MICs, $4 mg/ml; zone, #8 mm)
were applied to these data, 1 and 5% of minor and very major
errors (false susceptible) were detected. Modifying the colistin
disk diffusion resistant and susceptible zone diameters to #10
and $14 mm slightly improved error rates by decreasing very
major errors to 3.5% but increased the minor error rate to
1.5%. All but one error observed occurred among Acineto-
bacter spp. (two) and S. maltophilia isolates (seven).
Based on the long-established polymyxin B susceptibility
interpretative criteria (MICs, $4 mg/ml; zones, $8 mm), 12
strains would present discrepant results between test methods
(Fig. 3). All errors represented false-susceptible results (6.0%;
very major errors). Most errors occurred with S. maltophilia
(seven) and Acinetobacter spp. (three). Even if the zone diam-
eters were modified as suggested for colistin, the percentage of
false-susceptible results would not be diminished.
Determination of polymyxin QC. The disk diffusion QC re-
sults for the colistin and polymyxin B disks tested against E.
coli ATCC 25922 and P. aeruginosa ATCC 27853 are shown in
Table 3. The number of occurrences at each zone diameter
determined by various readers were compared and demon-
strated minimal variation between technologists. For the 120
colistin zone diameters produced (three disks, four observers,
and 10 replicates), the modal zone diameters were 18 and 17
mm for E. coli ATCC 25922 and P. aeruginosa ATCC 27853,
respectively. The interval derived from calculating the two
standard deviations above and below the mean (17.8 mm)
contains 95% of the results, and the modified QC ranges of
zones suggested would be 16 to 20 mm and 15 to 19 mm for the
FIG. 2. Scattergram comparing broth microdilution MICs and 10-mg disk zone diameters for colistin tested against 200 contemporary clinical
isolates. The solid lines represent the breakpoint values contained in reference 15, while the broken lines show the proposed new breakpoint values
for colistin.
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E. coli ATCC 25922 and P. aeruginosa ATCC 27853 strains,
respectively.
The 300-U polymyxin B disk zone diameters ranged from 17 to
20 mm for the E. coli ATCC 25922, with a mean and mode at 19
mm. Although the polymyxin B zones varied from 17 to 22 mm
for P. aeruginosa ATCC 27853, the mean and mode was the same
as that observed for the E. coli strain (19 mm). Using the same
statistical method applied to the colistin disk tests, the modified
QC ranges suggested would be 17 to 20 mm (4 mm) for E. coli
ATCC 25922 and 17 to 21 mm (5 mm) for P. aeruginosa ATCC
27853. The proposed ranges would include nearly all ($99.5%)
values obtained within the limits. These ranges were significantly
larger than those listed in the disk product package insert.
DISCUSSION
Emerging resistance in gram-negative bacilli has produced
the necessity for the parenteral use of polymyxins associated
FIG. 3. Scattergram comparing broth microdilution MICs and 300-U disk zone diameters for polymyxin B tested against 200 contemporary
clinical isolates. The solid lines represent the breakpoint values contained in reference 15, while the broken lines show the proposed new
breakpoint values for colistin (see Fig. 2).
TABLE 3. Colistin and polymyxin disk diffusion QC results for E. coli ATCC 25922 and P. aeruginosa ATCC 27853 (120 to 200 observations)
Antimicrobial disk and QC strain
No. of positive isolates at zone diam (mm) of: % isolates in range
15 16 17 18 19 20 21 22 PIa Proposedb
Colistin
E. coli ATCC 25922 0 4a 33b 70b 12b 1b 0 0 0.0 100.0
P. aeruginosa ATCC 27853 8b 36b 70b 6b 0b 0 0 0 NDc 100.0
Polymyxin B
E. coli ATCC 25922 0 1a 9b 79b 89b 22b 0 0 0.5 99.5
P. aeruginosa ATCC 27853 0 0 3b 35b 90b 64b 7b 1 ND 99.5
a PI, package insert range. Current PI ranges were: for colistin, E. coli ATCC 25922 at 11 to 15 mm, and for polymyxin B, E. coli ATCC 25922 at 12 to 16 mm.
b The proposed QC ranges from cited experiments were: for colistin, E. coli ATCC 25922 at 16 to 20 mm, and P. aeruginosa ATCC 27853 at 15 to 19 mm; for
polymyxin B, E. coli ATCC 25922 at 17 to 20 mm, and for P. aeruginosa ATCC 27853 at 17 to 21 mm.
c PI zone diameter ranges were not defined (ND) for P. aeruginosa ATCC 27853.
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with the need for reliable susceptibility methods to predict the
clinical response. In the 1970s, the NCCLS published the
breakpoints of susceptibility for colistin and polymyxin B (15).
However, at that time the procedures for standardization of
susceptibility testing, the establishment of interpretative break-
points, and the definition of QC strains guidelines were less
rigorous (18). With the introduction of aminoglycosides and
broad-spectrum b-lactams into clinical practice for the treat-
ment of gram-negative infections, the use of polymyxins be-
came very uncommon and was generally restricted to topical
indications. This led to the NCCLS removal of these agents
from the list of drugs suggested for testing and reporting (16).
The activity of polymyxins against P. aeruginosa isolates has
been widely known. One of the objectives of this study; how-
ever, was to observe if the polymyxins remain effective against
routine contemporary clinical isolates of P. aeruginosa and also
against multiresistant nonfermentative isolates such as Acin-
etobacter spp. and S. maltophilia. Results proved that both
polymyxin B and colistin were very active against recent P.
aeruginosa and Acinetobacter spp. isolates, and our observa-
tions agreed with other published reports (1, 4, 13). All P.
aeruginosa isolates, including the carbapenem nonsusceptible
isolates, were inhibited at #2 mg/ml concentrations of colistin
and polymyxin B. Although the polymyxins had also been very
active against Acinetobacter spp., with nearly 95.0% of isolates
being inhibited by MICs of #2 mg/ml, three carbapenem-re-
sistant Acinetobacter isolates also showed reduced susceptibil-
ity to colistin and polymyxin B (MICs of $4 for colistin and
polymyxin B). These isolates were obtained from infected pa-
tients in the United States and Brazil. The clinical significance
of the reduced susceptibility to polymyxins observed among
these isolates is currently under investigation. If the reduced
susceptibility to polymyxins correlates with a poor clinical re-
sponse, the situation will be disastrous, leaving no efficacious
drug for the treatment of serious infections caused by multi-
drug-resistant Acinetobacter spp. strains.
Although P. aeruginosa strains resistant to polymyxins were
not detected in this study, polymyxin-resistant isolates have
been described (9, 14). Polymyxin B and colistin show near-
complete cross-resistance (6, 7), and two types of resistance to
polymyxin B have been observed in P. aeruginosa: low-level,
transmissible mutations and high-level stepwise resistance, that
is unstable without the presence of polymyxin (9, 14). Nikas
and Hancock proposed that the P. aeruginosa outer membrane
protein OprH blocks the self-promoted uptake pathway. Thus,
the overexpression of OprH caused by mutation or as a result
of adaptation to an Mg21-deficient medium can be associated
with resistance to polymyxin B, aminoglycosides, and EDTA
(19, 20).
When the polymyxins were tested by dilution methods, two
distinct bacterial populations (very susceptible and resistant)
could be easily distinguished. Based on the bacterial popula-
tion distribution, we suggest that the long-used resistance
breakpoint applied to colistin and polymyxin B remain at $4
mg/ml, a level easily achievable in serum following intravenous
administration (6, 7, 11). The agar dilution and broth microdi-
lution methods showed excellent agreement for testing colistin
and polymyxin B. Only three bacterial isolates showed discords
($2-log2 dilutions) between the dilution methods, but these
differences resulted in very limited one-dilution error.
The correlation between the MICs and disk diffusion zone
diameters can be expressed mathematically by a regression line
analysis or compared by error rate bounding. The regression
line and acceptable correlation coefficients can be misleading if
applied from data that fails to disperse evenly among the entire
range of MIC values observed for the colistin and polymyxin B
data (2). Using previously published (15) or the modified
(#10- and $14-mm) disk diffusion zones proposed here for the
polymyxins, the percentages of false-susceptible errors for
colistin (5.0 or 3.5%) and polymyxin B (6.0%) were clearly and
reproducibly unacceptable. The majority of false-susceptible
errors occurred among S. maltophilia isolates. These results
were influenced in part by the fact that the disk diffusion test
has been determined to be an unreliable method for S. malto-
philia testing. Furthermore, false-susceptible errors were also
detected among other species such as Acinetobacter spp. and,
rarely, Enterobacter cloacae. Therefore, we suggest that results
of the disk diffusion test should be confirmed with a dilution
method, especially when polymyxin use is required for the
treatment of serious systemic infections caused by species
other than P. aeruginosa. The disk testing problem was further
complicated by erroneous QC zone diameter ranges found in
product package inserts for gram-negative strains suggested by
the NCCLS (16–18).
Due to its ability to bind strongly to the lipopolysaccharides
of gram-negative bacteria and membranes, formulations such
as polymyxin B-dextran 70 and covalent polymyxin B conju-
gated with human immunoglobulin G have been used as an
adjuvant therapy of septic shock (3, 5, 8). These combination
agents reduce the polymyxin toxicity profiles. However, these
“sepsis treatment” agents have negligible antimicrobial activ-
ity, even against highly susceptible gram-negative species such
as P. aeruginosa.
Further studies evaluating contemporary pharmacokinetics
and pharmacodynamics, toxicity, and the clinical response of
parenteral polymyxin regimens appear warranted. To perform
such studies, the restandardization of antimicrobial suscepti-
bility methods for polymyxins becomes essential (18). Mean-
while, the parenteral use of polymyxins should be restricted to
the treatment of infections caused by P. aeruginosa or possibly
Acinetobacter spp. strains resistant to less-toxic antimicrobial
agents. It appears that the footnote warning found in reference
15 still applies: “colistin and polymyxin B diffuse poorly in agar,
and the diffusion method is thus less accurate. Resistance is
always significant, but when treatment of infections caused by
a susceptible strain is being considered, results of a diffusion
test should be confirmed with a dilution method. MIC corre-
lates cannot be calculated reliably from regression analysis.”
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